38. Vasculitis in Systemic Lupus Erythematosus

  1. Gary S. Hoffman MD, MS2,
  2. Cornelia M. Weyand MD, PhD3,
  3. Carol A. Langford MD, MHS2 and
  4. Jörg J. Goronzy MD, PhD3
  1. Ricardo Garcia MD and
  2. Andras Perl MD, PhD

Published Online: 3 MAY 2012

DOI: 10.1002/9781118355244.ch38

Inflammatory Diseases of Blood Vessels, Second Edition

Inflammatory Diseases of Blood Vessels, Second Edition

How to Cite

Garcia, R. and Perl, A. (2012) Vasculitis in Systemic Lupus Erythematosus, in Inflammatory Diseases of Blood Vessels, Second Edition (eds G. S. Hoffman, C. M. Weyand, C. A. Langford and J. J. Goronzy), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781118355244.ch38

Editor Information

  1. 2

    Department of Rheumatic and Immunologic Diseases, Center for Vasculitis Care and Research, Cleveland Clinic, Lerner College of Medicine, Cleveland, OH, USA

  2. 3

    Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA

Author Information

  1. Division of Rheumatology, State University of New York, Upstate Medical University, Syracuse, NY, USA

Publication History

  1. Published Online: 3 MAY 2012
  2. Published Print: 8 JUN 2012

ISBN Information

Print ISBN: 9781444338225

Online ISBN: 9781118355244



  • SLE;
  • lupus;
  • vasculitis;
  • demography;
  • pathogenesis;
  • diagnosis;
  • histology;
  • antinuclear antibodies;
  • imaging;
  • treatment


Systemic lupus erythematosus is an autoimmune inflammatory disease of unknown origin. The pathogenesis has been attributed to the dysfunction of T and B cells, dendritic cells (DC) and macrophages, the production of antinuclear antibodies and the formation of immune complexes (IC). Tissue organ damage is most often caused by the inflammation of blood vessel walls resulting from the deposition of antibodies, IC and complement as well as from the release of destructive enzymes and reactive oxygen intermediates by infiltrating leukocytes which can affect nearly every organ of the body. Synthesis of clinical findings, histology, laboratory testing and imaging is usually required to make definitive diagnosis. Timely and aggressive treatment with conventional and biomarker-targeted immunosuppressant has markedly improved survival over the last decades.